Teva recall heart drug after carcinogen found in API

04:01 EDT 14 Jun 2019 | Pharmafile

Teva Pharmaceuticals has expanded its recall of losartan potassium tablets after detecting a possible carcinogen in an active pharmaceutical ingredient (API).

The Israeli drugmaker has expanded the recall to include six more batches of the drug after finding the possible carcinogen N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in an API.

The NMBA in the drugs was detected in an API manufactured by Indian firm Hetero Labs Limited. The API had been used to manufacture six bulk loads of the drug.

read more

Original Article: Teva recall heart drug after carcinogen found in API


More From BioPortfolio on "Teva recall heart drug after carcinogen found in API"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...